The Role of Metastasectomy and Immunochemotherapy in Multimodal Therapy for Metastatic Renal Cell Carcinoma.
- Author:
Sang Wohn CHON
1
;
Seung Hyun JEON
;
Sung Goo CHANG
Author Information
- Publication Type:Original Article
- Keywords: Renal cell carcinoma; Metastasis; Immunotherapy
- MeSH: Brain; Carcinoma, Renal Cell; Colon; Follow-Up Studies; Humans; Immunotherapy; Kidney; Lung; Metastasectomy; Neoplasm Metastasis; Nephrectomy; Retrospective Studies; Survival Rate
- From:Korean Journal of Urology 2008;49(1):1-6
- CountryRepublic of Korea
- Language:Korean
- Abstract: PURPOSE: One third of renal cell caricinoma(RCC) patients present with metastatic disease and 20-40% of these patients who undergo nephrectomy for clinically localized RCC will develop metastases. Eventually, the number of those patients who develop metastatic disease will increase to 30-50%. The aim of this study is to compare the efficacy and survival rate in relation to the time of performing metastasectomy and immnuochemotherapy. MATERIALS AND METHODS: We retrospectively enrolled 12 patients who had undergone radical nephrectomy, immunochemotherapy and metastasectomy between 1998 and 2007. The patients were subdivided into two groups. Group 1 included the patients who received radical nephrectomy, metastasectomy and immunochemotherapy altogether. Group 2 included the patients who developed metachronous metastases during follow-up after radical nephrectomy and so they then underwent metastasectomy and immunochemotherapy. We compared the survival rates between the two groups. RESULTS: The sites of initial metastasis were found to be 8 cases of lung metastasis, 2 of bone metastasis, 1 of brain metastasis and 1 of colon metastasis. The 5-year survival rate of the 5 patients from group 1 was 37.5%. In group 2, the 5-year survival rate of the 7 patients was 71.4% and the disease-free mean interval between primary resection of the kidney and metastasectomy was 36.43+/-7.62 months. Statistically, there was no significant difference of survival rates between the two groups. CONCLUSIONS: The results of this study suggest that metastasectomy followed by radical nephrectomy results in a longer survival time for the patients with metastatic cancer than that of patient that undergo radical nephretomy, metastasectomy and immunotherapy at the same time. We can recommend metastasetomy any time for the RCC patients who have technical resectable metastases with possibly positive prognostic factors and a good functional condition.
